Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Aug 21, 2016

166_ip_2016-08-21_67ae2b3b-71bd-4c7c-9210-ee2d04363fd5.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

A Leading Global Health Care Group

Frankfurt stock exchange: FRE │ US ADR program: FSNUY │ www.fresenius.com/investors

General Presentation, Fresenius SE & Co. KGaA, Investor Relations © Copyright, August 2016 1

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

A Global Leader In HealthCare Products And Services

~€27.6 bn in Sales

Strong portfolio of products (30% of sales) and services (70% of sales)

(as of Dec. 31, 2015) Total Shareholder Return: 10-year CAGR: ~20%

Global presence in 100+ countries

222,000+ employees worldwide (as of Dec 31, 2015)

Strong, Diversified Product And Service Portfolio

ly
du
l
Su
l
l
Op
l
D
ia
is
Pr
ts
Ho
i
ta
ies
Ho
i
ta
t
io
Ho
i
ta
Pr
j
ts
s
o
c
sp
p
p
sp
er
a
ns
sp
o
ec
He
l
hc
Se
ice
d
Se
ice
d
Se
ice
t
a
ar
e
rv
s
an
rv
s
an
rv
s		 Sa
le
2
0
S
\$
6.
bn
1
5:
U
1
7
s		 Sa
le
2
0
€
6.
0
bn
1
5:
s		 Sa
le
2
0
€
6
bn
1
5:
5.
s		 Sa
le
2
0
€
bn
1
5:
1.
1
s

Aging Population And Higher Incidence of Chronic Diseases

6
0
+		 l
d
l
W
i
6
0
t
+
o
r
p
o
p
u
a
o
n
a
g
e
1
i
l
l
h
2
b
b
2
0
0
5
>
n
w
r
e
a
c
y
8
0
+		 l
d
l
W
i
8
0
t
+
o
p
o
p
a
o
n
a
g
e
r
u
1
l
l
h
i
l
l
i
b
i
4
0
0
2
0
5
0
w
r
e
a
c
m
o
n
y
~
8
f
l
d
l
l
l
l
I
2
0
5
0
0
%
i
i
n
o
o
e
r
p
e
o
p
e
w
v
e
,
1
i
l
i
d
i
k
D
E
M
t
n
e
v
e
o
p
n
g
a
n
m
e
r
g
n
g
a
r
e
s
5
2
m		 h
d
h
D
C
i
D
i
t
t
e
a
s
e
o
o
n
s
e
a
s
e
s
a
e
u
r
c
r
d
f
l
l
j
i
3
8
i
i
t
t
p
r
o
e
c
e
o
n
c
r
e
a
s
e
r
o
m
m
o
n
2
2
0
2
2
i
l
l
i
b
2
0
3
0
i
1
5
t
n
o
m
o
n
y

Source: 1 WHO: 10 facts on aging and the life course WHO: Global status report on non communicable diseases

Increasing Health Care Spending

Increasing health expenditure

per capita (2014 vs. 2004 - USA US\$9,403 (+147%), China: US\$420 (+592%), India: US\$75 (+277%)1

1/3

By 2022, one third of all global health expenditure will occur in Emergin g Economies 2

~4%

Health care spendin g in developed countries is growin g steadily (2012-2022 with ~4% p.a. 2)

Source: 1 World Bank: Health expenditure per capita; 2World Economic Forum: Health Systems Leapfrogging in Emerging Economies – Project Paper (2014)

Fresenius Medical Care: Global Dialysis Market Leader

  • The world's leading provider of dialysis products and services treating 294,043 patients in 3,432 clinics1
  • Provide highest standard of product quality and patient care

Dialysis products

Dialysis services

Complete therapy offerings

Expansion in Care Coordination and global dialysis service opportunities; enter new geographies

Market Dynamics

Global Dialysis Market 2015: ~US\$73 bn; ~6% patient growth p.a.

Growth Drivers: Aging population, increasing incidence of diabetes and high blood pressure, treatment quality improvements

1As of Mar 31, 2016

Fresenius Medical Care: Strong Track Record Of Growth

2,327

Fresenius Kabi: A Leading Global Hospital Supplier

  • Comprehensive product portfolio for critically and chronically ill patients
  • Strong Emerging Markets presence
  • Leading market positions in four product segments

Focus on organic growth through geographic product rollouts and new product launches

Market Dynamics

Global Addressable Market 2015: >€33 bn

Growth Drivers: Patent expirations, rising demand for health care services, higher health care spending in Emerging Markets

Fresenius Kabi: Impressive Growth

Fresenius Helios: Leading German Hospital Operator

  • ~6% share in German acute care hospital market
  • Strong track record in hospital acquisitions and operations
  • High-quality medical care, e.g., mortality rate for heart failure and pneumonia below German average
  • Comprehensive healthcare services coverage

German Acute Care Hospital Market: ~€91 bn1

Growth Drivers: Aging population leading to increasing hospital admissions, further market consolidation

Majority of population has access to a HELIOS hospital within one hour's drive1

Outpatient

1 German Federal Statistical Office 2015; total costs, gross of the German hospitals less academic research and teaching 1 As of Dec 31, 2015

  • 111 hospitals

  • 34,000 beds

  • ~1.3 million inpatient admissions
  • ~3.4 million outpatient admissions

Fresenius Helios: Excellent Sales And EBIT Development

Fresenius Vamed: Leading Global hospital Projects And Services Specialist

Manages hospital construction/expansion projects (51% of sales) and provides services (49% of sales) for health care facilities worldwide

Projects

Services

  • Offers project development, planning, turnkey construction, maintenance as well as technical management, and total operational management
  • Strong track record: More than 760 projects in 78 countries completed

Market Dynamics

Growth Drivers:

Emerging Market demand for building and developing hospital infrastructure

Outsourcing of non-medical services from public to private operators

Fresenius Vamed: Steady Sales And EBIT Growth

64

Fresenius Group: Excellent Financial Performance Driven By Organic Growth And Acquisitions

Net income in € million

Earnings per share in €

Fresenius Group: Consistent Cash Generation And Proven Track Record of Deleveraging

Capex in % of sales

Net Debt / EBITDA1

1 2011-2015 adjusted due to debt issuance cost restatement (U.S. GAAP standard ASU 2015-03)

Total Shareholder Return – CAGR, rounded

Source: Bloomberg; dividends reinvested

Fresenius Group: 2016 Financial Outlook by Business Segment

O
l
d		 N
e
w
S
l
h
t
i
a
e
s
g
r
o
w
o
r
g
a
n
c		 l
l
d
i
i
i
t
o
w
s
n
g
e
g
-		 3
%
%
5
–
E
B
I
T
t
t
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 h
l
f
l
t
o
g
a
r
u
y		 3
%
5
%
–
l
h
S
i
t
a
e
s
g
r
o
w
o
r
g
a
n
c		 3
%
5
%
–		 h
d
u
n
c
a
n
g
e
E
B
I
T		 €
6
0
0
0
7
7
m
–		 h
d
u
n
c
a
n
g
e
l
h
S
i
t
a
e
s
g
o
o
g
a
n
c
r
w
r		 5
%
1
0
%
–		 h
d
n
c
a
n
g
e
u
h
E
B
I
T
t
g
r
o
w		 %
0
%
5
1
–		 h
d
u
n
c
a
n
g
e

Fresenius Group: 2016 Financial Guidance

2
0
1
5
l
A
t
c
u
a		 2
0
1
6
O
l
d		 N
e
w
l
h
S
t
a
e
s
g
o
r
w		 b
€
2
7
6
n		 6
%
8
%
–		 h
d
n
a
n
g
e
u
c
t
t
c
o
n
s
a
n
c
u
r
r
e
n
c
y
1
i
N
t
e
n
c
o
m
e
h
t
g
o
r
w		 €
2
3
1,
4
m		 8
%
2
%
1
–		 %
%
1
1
1
4
–
t
t
c
o
n
s
a
n
c
u
r
r
e
n
c
y

1 Net income attributable to shareholders of Fresenius SE&Co.KGaA; 2015 before special items

Fresenius Group: Confirming mid-term growth targets

2019: €36 - 40 billion in sales€2.0 - 2.25 billion in net income

At comparable exchange rates

Includes small and mid-size acquisitions

EAT CAGR at mid-point of mid-term target: 10.5% (Previous implied EAT CAGR of mid-term target: 8.4%)

Net income attributable to shareholders of Fresenius SE&Co.KGaA; 2015 before special items

Investment Highlights

Share Information

Share key facts

1
b
f
h
N
m
e
o
s
a
e
s
u
r
r		 6,
3
3
2
6
5
4
5
5,
/
S
W
K
N
I
I
N		 8
6
0
/
0
0
0
8
6
0
5
7
5
D
E
5
7
5
4
T
i
k
b
l
c
e
r
s
y
m
o		 F
R
E
l
b
b
l
B
o
o
m
e
g
s
m
o
r
y		 F
R
E
G
R
b
l
R
t
e
e
s
s
m
o
u
r
y		 d
F
R
E
G
e

ADR key facts

R
i
t
o
a		 d
h
4
A
D
R
1
i
o
n
e
s
r
a
r
y
s
a
r
=
/
A
D
R
C
U
S
I
P
I
S
I
N		 /
3
5
8
0
4
M
1
0
5
U
S
3
5
8
0
4
M
1
0
5
3
k
b
l
T
i
c
e
r
s
y
m
o		 S
F
N
U
Y
h
E
x
c
a
n
g
e		 O
C
Q
i
l
i
T
X
I
t
t
P
n
e
r
n
a
o
n
a
r
e
m
e
r
S
t
t
r
u
c
u
r
e		 d
l
S
L
I
A
D
R
p
o
n
s
o
r
e
e
v
e
b
k
D
i
t
e
p
o
s
a
a
n
r
y		 h
k
D
B
t
e
s
c
e
a
n
u

1As of July 31, 2016

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.